Posttransplant hypertension is a major risk factor for cardiovascular disease and chronic renal allograft dysfunction. A significant number of transplant recipients suffer from posttransplant hypertension in part because of corticosteroid and calcineurin inhibitor use. Although the optimal blood pressure range and the antihypertensive agents of choice in the transplant population have not been determined, the guidelines for blood pressure control in the general population can be extrapolated to the transplant population. The choice of an antihypertensive regimen should be tailored on the basis of the individual patient's risk factors and comorbidities.
Get full access to this article
View all access options for this article.
References
1.
US Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.2002–2003. Available at: http://www.usrds.org/reference.htm. Accessed August 11, 2003.
2.
PruthiJMedkiffKAEsrasonKT. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transplant.2001;7:811–815.
3.
VogtDPHendersonJMCareyWD. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery.2002;132:775–780.
4.
LewingtonSClarkeRQizilbashN. Age-specific relevance of usual blood pressure to vascular mortality. Lancet.2002;360:1903–1903.
5.
NealBMacMahonSChapmanN. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet.2000;356:1955–1964.
6.
OpelzGWujciakTRitzE. Association of chronic kidney graft failure with recipients blood pressure. Kidney Int.1998;53:217–222.
7.
JensikSC. Tacrolimus (FK 506) in kidney transplantation: Three-year results of the US multicenter, randomized, comparative trial. Transplant Proc.1998;30:1216–1218.
8.
VincentiFJensikSCFiloRS. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation.2002;73:775–782.
9.
OttoMGMayerADClavienPACavallariAGunawardenaKAMuellerEA. A long-term comparison of tacrolimus (FK 506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation.2002;73:775–782.
10.
CanzanelloVJTextorSCTalerSJ. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK 506). Liver Transplant Surg.1998;4:328–334.
11.
EisenHJHobbsREDavisSF. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine—results at 24 months after transplantation. Transplantation.2001;71:70–78.
12.
EisenHJHobbsREDavisSF. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporin—results at six months after transplantation. Transplantation.1999;68:663–671.
13.
WhitworthJA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int.1987;31:1213–1224.
14.
HricikDELautmanJBartucciMR. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated transplant recipients. Transplantation.1992;53:1232–1236.
15.
MossNGPowellSLFalkRJ. Intravenous cyclosporine acticates afferent and efferent renal nerves and causes sodium retension in innervated kidneys in rats. Proc Natl Acad Sci USA.1985;82:8222–8226.
16.
MarsenTAWeberFEginkGSuckauGBaldamusCA. Cyclosporine A induces prepro endothelin-1 gene transcription in human endothelial cells. Eur J Pharmacol.1999;379:97–106.
17.
OrijiGKKeiserHR. Nitric oxide in cyclosporine A-induced hypertension: Role of protein kinase C. Am J Hypertens.1999;12:1091–1097.
18.
ScherrerUVissinSFMorganBJ. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med.1990;323:693–699.
19.
AvdoninPVCottet-MarieFAfanasjevaGV. Cyclosporine A upregulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int.1999;55:2407–2414.
20.
TextorSC. De novo hypertension after liver transplantation. Hypertension.1993;22:257–267.
21.
WongWFynSPHigginsRM. Transplant renal artery stenosis in 77 patients—does it have an immunological cause?Transplantation.1996;61:215–219.
22.
FervenzaFCLafayetteRAAlfreyEJPetersenJ. Renal artery stenosis in kidney transplants [review]. Am J Kidney Dis.1998;31:142–148.
23.
DuclouxDMotteGKribsM. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol.2002;57:409–413.
24.
VanrenterghemYWaerMChristiaesMRMichielsenP. Bilateral nephrectomy of the native kidneys reduces the incidence of arterial hypertension and erythrocytosis in kidney graft recipients treated with cyclosporin. Transplant Int.1992;5(suppl 1):S35–37.
25.
WomerKLVellaJPSayeghMH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol.2000;20:126–147.
26.
ChobanianAVBakrisGLBlackHR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA.2003;289:2560–2572.
27.
MangeKCFeldmanHIJoffeMMFaKBloomRD. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol.2004;15:187–193.
28.
OlyaeiAJdeMattosAMBennettWM. A practical guide to the management of hypertension in renal transplant recipients. Drugs.1999;58:1011–1027.
29.
BarolettiSAGabardiSMageeCC. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: Fact or fiction. Pharmacotherapy.2003;23:788–801.
30.
SchlueterWABatlleDC. Renal effects of antihypertensive drugs. Drugs.1989;37:900–925.
31.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med.1997;157:2413–2446.
32.
Venkat-RamanGFeehallyJElliotHL. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Nephrol Dial Transplant.1998;13:2612–2616.
33.
WagnerKAlbrechtSNeumayerHH. Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: A prospective randomized study. Am J Nephrol.1987;7:287–291.
34.
McMillenMALewisTJaffeBM. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res.1985;39:76–80.
35.
BirxDLBergerMFleisherTA. The interference of T cell activation by calcium channel blocking agents. J Immunol.1984;133:2904–2909.
36.
PalmerBFDawidsonISagalowskyA. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation.1991;52:640–645.
37.
RumpLCOberhauserVSchwertfegerE. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens.2000;18:1115–1119.
38.
van RiemsdijkICMulderPGde FijterJW. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation.2000;70:122–126.
39.
JamesJAMarleyJJJamalS. The calcium channel blocker used with cyclosporin has an effect in gingival overgrowth. J Clin Periodontol.2000;27:109–115.
40.
KhooriAHEinollahiBAnsariG. The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. J Can Dent Assoc.2003;69:236–241.
41.
AsbergAChristensenHHartmannACarlsonEMoldenEBergKJ. Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol.1999;55:383–387.
42.
HebertMFLamAY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother.1999;33:680–682.
43.
GuanDWangRLuJWangMXuC. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc.1996;28:1311–1312.
44.
CrockerJFRentonKWLeVatteTLMcLellanDH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol.1994;8:408–411.
45.
PesaventoTEJonesPAJulianBACurtisJJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study. J Am Soc Nephrol.1996;7:831–835.
46.
ToupanceOLavaudSCanivetEBernaudCHottonJMChanardJ. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension.1994;24:297–300.
47.
LewisEJHunsickerLGBainRPRohdeRD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med.1993;329:1456–1462.
48.
BrennerBMCooperMEde ZeeuwD. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med.2001;345:861–869.
49.
LewisEJHunsickerLGClarkeWR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001;345:851–860.
50.
WrightJTJrAgodoaLContrerasG. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med.2002;162:1636–1643.
51.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet.1997;349:1857–1863.
52.
CurtisJJLaskowDAJonesPAJulianBAGastonRSLukeRG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol.1993;3:1570–1574.
53.
HausbergMKoschMHohageH. Antihypertensive treatment in renal transplant patients—is there a role for ACE inhibitors?Ann Transplant.2001;6:31–37.
54.
RemuzziGPericN. Routine renin-angiotensin system blockade in renal transplantation?Curr Opin Nephrol Hypertens. January 2002;11:1–10.
55.
LinJValeriAMMarkowitzGS. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation.2002;73:783–788.
56.
CaloLADavisPAGiaconB. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: Effect of ramipril. J Cardiovasc Pharmacol.2002;400:625–631.
57.
AsbergAMidtvedtKVassbotnTHartmannA. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant.2001;16:1465–1470.
SchmidtAGruberUBohmigGKollerEMayerG. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant.2001;16:1034–1037.
GlicklichDKapoianTMianHGilmanJTellisVCrizatH. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation. July 1999;68:62–66.
62.
MazzaliMFilhGA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation.1998;65:1461–1464.
63.
YildizACineNAkkayaV. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: Prospective randomized study. Transplantation.2001;72:542–544.
64.
The ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA.2000;283:1967–1975.
